India-based Ranbaxy has had a presence in Russia since 1993 when it launched its antibiotic, Cifran (ciprofloxacin). Since then, Ranbaxy has grown to become a major player in the Russian market with a market share of 15.4%.

The company has registered 51 drugs in the Russian Federation in the areas of anti-infective, cold, pain management, cardiovascular, diabetology, central nervous system, urology and dermatology treatments.

The company is now looking at further expanding its product portfolio to include value added and innovator products from Ranbaxy’s parent company, Daiichi Sankyo. Ranbaxy is also ‘working closely in partnership with regional governments in line with the Russia Pharma, 2020 Healthcare Plan’, according to Ranbaxy’s Country Head of Russia, Mr Aman Khanna. Under the plan Russia aims to increase local producers' share of total drug sales from its current 20% to 50% by 2020 [1].

The Russian pharmaceutical market is estimated at around US$20 billion, with a compound annual growth rate of around 11%. Russia has also recently opened discussions on how to harmonize Russia’s regulatory standards for biologicals with the rest of the world to develop a framework for pharmaceutical companies developing biologicals and biosimilars in Russia [2], making it an increasingly attractive market for international pharmaceutical companies.

Related article

Kazakhstan, Russia, Ukraine to change drug reimbursement schemes

References

1.  GaBI Online - Generics and Biosimilars Initiative. Russian drug spending set to reach US$4 billion by 2020 [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 13]. Available from: www.gabionline.net/Policies-Legislation/Russian-drug-spending-set-to-reach-US-4-billion-by-2020

2.  GaBI Online - Generics and Biosimilars Initiative. Russia to harmonize biologicals regulations [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2013 Sep 13]. Available from: www.gabionline.net/Biosimilars/News/Russia-to-harmonize-biologicals-regulations

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.